Royalty Pharma (NASDAQ:RPRX) Announces Earnings Results

Royalty Pharma (NASDAQ:RPRX) posted its earnings results on Wednesday. The biopharmaceutical company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.27 by $0.05, Zacks reports. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. The firm had revenue of $674.14 million during the quarter, compared to analysts’ expectations of $758.93 million.

Here are the key takeaways from Royalty Pharma’s conference call:

• Royalty receipts grew 14% year over year in the second quarter, while portfolio receipts increased 6% to $773 million and portfolio cash flow reached $736 million, reflecting approximately 95% cash conversion.
• Royalty Pharma raised its 2026 guidance for the second consecutive quarter, now forecasting portfolio receipts of $3.4 billion to $3.5 billion and royalty-receipt growth of approximately 7% to 10%, despite expected headwinds from PROMACTA, TYSABRI biosimilars and the IRA.
• The company acquired a royalty on AstraZeneca’s cliramitug for up to $425 million, gaining a 3.75% worldwide sales royalty on a potential first-in-class treatment for transthyretin amyloid cardiomyopathy with projected peak royalties of approximately $110 million to $190 million.
• Royalty Pharma cited continued progress across its pipeline, including regulatory submissions and approvals, with 19 development-stage therapies and approximately $2 billion of potential peak royalties in the late-stage pipeline; key trial readouts are expected through 2027.
• The company ended June with $812 million in cash, $9.2 billion of investment-grade debt and leverage of 2.8 times adjusted EBITDA, while maintaining more than $4 billion of financial flexibility and returning approximately $367 million to shareholders in the first half.

Royalty Pharma Trading Down 1.2%

Shares of Royalty Pharma stock traded down $0.67 on Thursday, reaching $57.09. 1,275,922 shares of the company were exchanged, compared to its average volume of 3,548,046. Royalty Pharma has a fifty-two week low of $34.08 and a fifty-two week high of $60.44. The firm has a market capitalization of $32.87 billion, a price-to-earnings ratio of 38.76, a price-to-earnings-growth ratio of 10.18 and a beta of 0.43. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The stock has a fifty day moving average price of $56.39 and a 200-day moving average price of $50.30.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a dividend of $0.235 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.6%. Royalty Pharma’s payout ratio is 63.95%.

Wall Street Analyst Weigh In

RPRX has been the subject of several recent analyst reports. Weiss Ratings cut Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 15th. The Goldman Sachs Group restated a “buy” rating and set a $66.00 price objective on shares of Royalty Pharma in a research note on Thursday. Bank of America reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Wednesday. TD Cowen upped their price target on shares of Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $65.00 price objective on shares of Royalty Pharma in a report on Thursday. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma currently has an average rating of “Buy” and an average price target of $60.29.

Insider Buying and Selling

In other Royalty Pharma news, CFO Terrance P. Coyne sold 64,399 shares of the company’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $53.98, for a total transaction of $3,476,258.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.00, for a total transaction of $161,385.00. Following the sale, the director directly owned 191,803 shares of the company’s stock, valued at $10,165,559. This represents a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 393,009 shares of company stock worth $21,601,827. Company insiders own 18.84% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RPRX. CIBC Private Wealth Group LLC lifted its position in shares of Royalty Pharma by 66.4% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 446 shares in the last quarter. Larson Financial Group LLC raised its stake in Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 306 shares during the period. Smartleaf Asset Management LLC raised its stake in Royalty Pharma by 59.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,405 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 524 shares during the period. Transamerica Financial Advisors LLC lifted its holdings in shares of Royalty Pharma by 10.7% in the fourth quarter. Transamerica Financial Advisors LLC now owns 5,158 shares of the biopharmaceutical company’s stock valued at $199,000 after purchasing an additional 498 shares in the last quarter. Finally, Hilltop Holdings Inc. purchased a new stake in shares of Royalty Pharma in the third quarter valued at $205,000. 54.35% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Earnings beat expectations: Royalty Pharma reported adjusted earnings of $1.32 per share, exceeding the $1.27 analyst consensus and rising from $1.14 a year earlier. Royalty Pharma Q2 earnings report
• Positive Sentiment: Royalty receipts grew strongly: Portfolio Receipts increased 6% to $773 million, while Royalty Receipts grew 14%. Operating cash flow totaled $728 million, supporting the company’s ability to fund investments and shareholder returns. Royalty Pharma second-quarter results
• Positive Sentiment: Full-year guidance was raised: Management now expects 2026 Portfolio Receipts of $3.4 billion to $3.5 billion, indicating confidence in the underlying royalty portfolio and near-term cash generation. Royalty Pharma Q2 earnings call highlights
• Neutral Sentiment: Profitability remained solid: Royalty Pharma reported a 33.88% net margin and 29.25% return on equity, although investors may focus more on recurring royalty receipts than reported revenue and EPS.
• Negative Sentiment: Revenue missed estimates: Quarterly revenue of $674.14 million came in below the approximately $758.93 million analyst forecast. The miss may have overshadowed the EPS beat and strong cash-flow metrics. Royalty Pharma earnings results
• Negative Sentiment: Valuation may limit upside: Commentary characterized Royalty Pharma as attractive at a lower price but less compelling at current valuation levels, potentially encouraging profit-taking after its recent advance. Royalty Pharma valuation analysis

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.